Unknown Animal/Cell Subject Framework for Monitoring MS Progression
A new framework was proposed for monitoring multiple sclerosis (MS) by integrating clinical and cognitive measures with MRI and drug safety monitoring. It incorporates measures such as NEDA-3 and discusses enhancements like NEDA-4 and additional biomarkers. Complementary prognostic tools were identified, but some did not independently indicate treatment changes.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
This framework aims to standardize monitoring approaches for MS progression, potentially improving patient outcomes by considering various factors such as cognitive health and biomarkers.
What this does not prove
The study lacks formal risk-of-bias assessment, and the recommendations require validation in practice. Implementation must adapt to individual patient needs and healthcare resources.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-24
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceAn integrated framework for clinical surveillance in multiple sclerosis: An evidence-informed narrative review. ↗DOI: 10.1016/j.jns.2026.126191
Supporting passages (4)
publication date2026-09-24
findingsThe proposed framework integrates clinical and cognitive measures, conventional MRI and drug-specific safety monitoring.
limitationsNo formal risk-of-bias assessment or evidence grading was performed.
limitationsIts operational recommendations and monitoring tiers require prospective validation, and implementation should reflect patient characteristics, treatment-specific requirements and local resources.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.